Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. MDM2 is preferentially localized in the nucleus in LPS cells.
  • Fig. S2. MDM2 is preferentially recruited to chromatin in LPS cells.
  • Fig. S3. The MDM2-ATF4 complex regulates serine metabolism in LPS cells.
  • Fig. S4. MDM2 regulates serine metabolism in LPS.
  • Fig. S5. Nutlin-3A enhances serine metabolism in LPS.
  • Fig. S6. The pharmacological inhibitor SP141 inhibits MDM2-associated metabolic functions in nucleotide synthesis in DD-LPS cells.
  • Fig. S7. Stable isotope tracing experiments showing inhibition of MDM2-associated metabolic functions by SP141 in DD-LPS cells.
  • Fig. S8. Cell proliferation and survival defects upon pharmacological inhibition of MDM2 by SP141.
  • Fig. S9. MDM2 degrader as a potential therapeutic strategy for LPS.
  • Fig. S10. MDM2 metabolic function as a potential therapeutic strategy for LPS.
  • Fig. S11. Characterization of PDX models of sarcomas.
  • Fig. S12. Inhibition of MDM2-mediated control of serine metabolism as a potential therapeutic strategy for LPS.
  • Table S1. Sarcoma cell lines.
  • Table S2. Characterization of PDX models.
  • Table S3. Primers for qPCR.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Individual data from sample sizes (n < 20 per group).